| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| ln Vitro |
At 1.2 M of L-Alanine, the viability of 201B7 cells and ehiPSCs decreases to 7.5±1.3% and 3.7±0.7%, respectively, as the concentration of L-Alanine increases. The viability of hFBs and hSkMCs, however, does not appear to have decreased. Although iCMs' vitality marginally declines as L-Alanine concentration rises, it is still considerably greater (p<0.01) than that of undifferentiated iPSCs, 201B7 cells, and ehiPSCs at 1.2 M concentration of L-Alanine (49.4±6.9%). Even after two or four hours of treatment, the vitality of 201B7 cells, hiPSCs, and ehiPSCs sharply declines. However, the viability of hFBs exhibits a slight decline at 24 hours of treatment, failing to decrease at 1, 2, and 4 hours. Following a 2-hour treatment with 1.2 M L-Alanine, the vitality of 201B7 cells in suspension culture drops to 11.8±6.0%, while that of hFBs is 72.9±14.2%[1].
|
|---|---|
| References | |
| Additional Infomation |
L-Alanine is the L-enantiomer of alanine. It is an EC 4.3.1.15 (diaminopropionic acid lyase) inhibitor and an important metabolite. It belongs to the pyruvate family of amino acids, is a protein-forming amino acid, and is also an L-α-amino acid, belonging to the alanine family. It is the conjugate base of L-alanine, the conjugate acid of L-alanine, an enantiomer of D-alanine, and a zwitterion tautomer of L-alanine. Alanine is a non-essential amino acid, existing in high concentrations in its free state in plasma. It is produced from pyruvate via transamination. It participates in the metabolism of sugars and acids, enhances immunity, and provides energy for muscle tissue, the brain, and the central nervous system. L-Alanine is a metabolite found in or produced by Escherichia coli (K12 strain, MG1655 strain). Alanine is an amino acid.
It has been reported that alanine is found in plants of the genus Euphorbia (such as creeping euphorbia and angelica) and other organisms with relevant data. Alanine is an essential small-molecule amino acid for the human body and one of the most widely used amino acids in protein synthesis, participating in the metabolism of tryptophan and vitamin pyridoxine. Alanine is an important energy source for muscles and the central nervous system, enhancing the immune system, aiding in the metabolism of sugars and organic acids, and having a cholesterol-lowering effect in animals. (NCI04) Alanine is a non-essential amino acid synthesized in the body from the conversion of carbohydrate pyruvate or DNA breakdown, as well as from dipeptides carnosine and anserine. It is highly concentrated in muscles and is one of the most important amino acids released from muscles, serving as a primary energy source. Plasma alanine levels are typically lower when branched-chain amino acids (BCAAs) are deficient. This finding may be related to muscle metabolism. Alanine is found in high concentrations in meat products and other high-protein foods such as wheat germ and cheese. Alanine is an important participant and regulator of glucose metabolism. In diabetes and hypoglycemia, alanine levels are positively correlated with blood glucose levels, and alanine can alleviate severe hypoglycemia and diabetic ketoacidosis. It is an important amino acid for lymphocyte proliferation and immunity. Alanine therapy has helped dissolve kidney stones in laboratory animals. Like other amino acids, normal alanine metabolism is highly dependent on enzymes containing vitamin B6. Alanine, along with GABA, taurine, and glycine, is an inhibitory neurotransmitter in the brain. It is produced from pyruvate via transamination. Alanine participates in the metabolism of sugars and acids, enhances immunity, and provides energy to muscle tissue, the brain, and the central nervous system. Alanine is a non-essential amino acid, existing in high concentrations in its free state in plasma. It is produced from pyruvate via transamination. Alanine participates in the metabolism of sugars and acids, enhances immunity, and provides energy to muscle tissue, the brain, and the central nervous system. See also: Glatiramer acetate (monomer); Glatiramer (monomer). Amliximod (monomer)...See more... Drug Indications For protein synthesis. Mechanism of Action L-alanine is a non-essential amino acid that exists in large quantities in the blood plasma in a free state. It is produced from pyruvate via transamination. It participates in the metabolism of sugars and acids, enhances immunity, and provides energy for muscle tissue, the brain, and the central nervous system. Branched-chain amino acids (BCAAs) are the energy source for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscle; their carbon skeleton is used as fuel, while their nitrogenous portion is used to synthesize another amino acid—alanine. Alanine is then converted into glucose in the liver. This energy production pathway is called the alanine-glucose cycle, which plays a crucial role in maintaining blood glucose balance in the body. |
| Molecular Formula |
C3H7NO2
|
|---|---|
| Molecular Weight |
89.09
|
| Exact Mass |
89.047
|
| CAS # |
56-41-7
|
| Related CAS # |
25191-17-7
|
| PubChem CID |
5950
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
212.9±23.0 °C at 760 mmHg
|
| Melting Point |
314.5 °C (dec.)(lit.)
|
| Flash Point |
82.6±22.6 °C
|
| Vapour Pressure |
0.1±0.9 mmHg at 25°C
|
| Index of Refraction |
1.460
|
| LogP |
-0.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
61.8
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H](C(=O)O)N
|
| InChi Key |
QNAYBMKLOCPYGJ-REOHCLBHSA-N
|
| InChi Code |
InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1
|
| Chemical Name |
(2S)-2-aminopropanoic acid
|
| Synonyms |
Alanine AlaninumL-(+)-Alanine Alanina NSC-206315 NSC206315NSC 206315
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~150 mg/mL (~1683.69 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (561.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 11.2246 mL | 56.1230 mL | 112.2460 mL | |
| 5 mM | 2.2449 mL | 11.2246 mL | 22.4492 mL | |
| 10 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00586885 | COMPLETED | Drug: L-alanine | Nonalcoholic Steatohepatitis | Keith D Lindor, M.D. | 2004-02 | Not Applicable |
| NCT01288495 | TERMINATED | Dietary Supplement: supplemental L-alanine
Dietary Supplement: Metamucil |
Dietary Fructose Intolerance | Augusta University | 2009-02 | Not Applicable |
| NCT05096793 | COMPLETED | Dietary Supplement: beta alanine | Beta-alanine | University of Americas | 2021-05-03 | Not Applicable |
| NCT01185210 | UNKNOWN STATUS | Dietary Supplement: Placebo Dietary Supplement: Alanine Dietary Supplement: Alanine |
Fructose Intolerance | Augusta University | 2007-09 | Not Applicable |
| NCT04022434 | UNKNOWN STATUS | Dietary Supplement: Placedo Dietary Supplement: Alanine |
Fructose Intolerance | Augusta University | 2014-01-07 | Not Applicable |
|
|
|